PACS Group (PACS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
18 May, 2026Executive summary
Revenue for Q1 2026 rose 11.2% year-over-year to $1.42 billion, with net income up 184% to $80.7 million and adjusted EBITDA up 75% to $170.4 million, reflecting strong occupancy, skilled mix, and operational execution.
Operated 323–324 facilities across 17 states, serving over 31,900 patients daily, with mature facilities maintaining high occupancy and clinical consistency.
Leadership transition announced: Carey Hendrickson appointed CFO, succeeding retiring co-founder Mark Hancock, with enhancements to compliance and internal audit functions.
Ongoing government and regulatory investigations continue, with full cooperation and strengthened compliance processes.
Portfolio expanded with acquisitions of three senior living facilities and underlying real estate for two, plus ongoing real estate investments.
Financial highlights
Q1 2026 revenue was $1.42 billion, up from $1.28 billion in Q1 2025; net income reached $80.7 million, up from $28.4 million.
Adjusted EBITDA was $170.4 million, a 75% increase year-over-year; Adjusted EBITDAR was $265.9 million.
Diluted EPS was $0.50, up from $0.17 in the prior year.
Cash flow from operations in Q1 2026 was $236.3 million.
Same-store revenue grew 8% year-over-year, driven by occupancy and skilled mix improvements.
Outlook and guidance
Full-year 2026 adjusted EBITDA guidance raised to $605–$625 million, representing ~22% growth over 2025.
Revenue guidance reaffirmed at $5.65–$5.75 billion, now excluding future acquisitions.
Guidance excludes unpredictable quality incentive payments (e.g., WQIP, Ohio), which will be reported as received.
Management expects current cash balances and operating cash flow to cover needs for at least the next 12 months.
Acquisition pipeline remains active, with ongoing evaluation of opportunities aligned with strategic and financial criteria.
Latest events from PACS Group
- Board elections, auditor ratification, and executive pay all approved without stockholder questions.PACS
AGM 202610 Jun 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.PACS
Proxy filing28 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PACS
Proxy filing28 Apr 2026 - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 202527 Feb 2026 - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 20241 Feb 2026 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Offering 2.78M shares at $39.67 to repay debt; founders retain control; strong growth, high regulatory risk.PACS
Registration Filing29 Nov 2025 - Shareholders will vote on director elections, auditor ratification, and executive compensation matters.PACS
Proxy Filing25 Nov 2025